Berlin, Germany – Health authorities in France are re-evaluating the drug Evenity (romosozumab) for the treatment of severe postmenopausal osteoporosis, a move that could impact treatment guidelines for women at high risk of fractures. The re-evaluation, announced by the Haute Autorité de Santé (HAS), comes as the agency seeks to refine its recommendations regarding the drug’s efficacy and cost-effectiveness.
Evenity, developed by Amgen, represents a novel approach to osteoporosis treatment. Unlike many existing therapies that slow bone loss, romosozumab is a monoclonal antibody designed to both increase bone formation and decrease bone resorption. This dual action aims to rapidly improve bone mineral density and reduce fracture risk. Though, its use has been subject to scrutiny, particularly concerning its potential cardiovascular risks and limitations in specific patient populations.
The HAS initially approved Evenity in March 2021, but with restrictions. Reimbursement was recommended only for women under 75 years of age with a history of severe fracture and no prior history of coronary heart disease. The agency expressed concerns about the drug’s efficacy in older patients and the potential for adverse cardiovascular events in those with pre-existing heart conditions. The initial assessment highlighted a “minor clinical added value” compared to established treatments like alendronate.
Current Restrictions and the Re-evaluation Process
The current re-evaluation is prompted by the need to reassess the drug’s place in the therapeutic strategy, considering new data and evolving clinical practice. The HAS is seeking input from healthcare professionals and patient organizations to inform its updated recommendations. The process involves a thorough review of clinical trial data, real-world evidence, and cost-effectiveness analyses.
Osteoporosis is a significant public health concern, particularly among postmenopausal women. The condition weakens bones, making them more susceptible to fractures, which can lead to pain, disability, and even death. According to the National Osteoporosis Foundation, approximately 10 million Americans have osteoporosis, and another 44 million have low bone density, placing them at risk. Statistics from the National Osteoporosis Foundation underscore the widespread impact of this disease.
The decision-making process for osteoporosis treatment is complex, relying on fracture risk assessment, bone mineral density (BMD) measurements, and consideration of other risk factors. Treatment options include lifestyle modifications (exercise, diet), calcium and vitamin D supplementation, and pharmacological interventions. Bisphosphonates, such as alendronate, are commonly used first-line treatments, but they have limitations, including potential side effects and the need for long-term adherence.
Clinical Added Value and Patient Selection
The HAS’s initial assessment of Evenity found “no clinical added value” in the overall therapeutic strategy. This finding was based on the available data at the time, which suggested that the drug’s benefits did not outweigh its risks and costs compared to existing treatments. However, the re-evaluation may consider new evidence that could alter this conclusion.
A key aspect of the re-evaluation will be to refine patient selection criteria. The initial restrictions limiting use to women under 75 with a history of severe fracture and no coronary heart disease were intended to mitigate potential risks. The HAS will likely examine whether these criteria are appropriate and whether they can be adjusted based on a more comprehensive understanding of the drug’s safety and efficacy profile.
The role of osteoporosis treatment is to prevent fractures by strengthening bone tissue and preventing falls. Before initiating specific treatment, correcting any vitamin D and/or calcium deficiency is crucial, particularly in older patients, through dietary adjustments and/or supplementation. Physical exercise and fall prevention strategies are also integral to managing osteoporosis patients. Medicinal fracture-prevention treatment is indicated only when there is a high fracture risk, as determined by BMD and other risk factors. A BMD T-score below -2.5 indicates osteoporosis, but a score between -2.5 and -3 is not sufficient to initiate treatment alone.
Cardiovascular Concerns and Ongoing Research
Concerns about the potential cardiovascular risks associated with Evenity have been a major factor in its restricted use. Clinical trials have raised questions about a possible increased risk of heart attack, stroke, and other cardiovascular events. The HAS will carefully review the available data on this issue, considering both the absolute risk and the relative risk compared to other osteoporosis treatments.
Research continues to investigate the long-term safety and efficacy of romosozumab. Studies are underway to assess its impact on cardiovascular outcomes and to identify patient subgroups who may be at higher or lower risk. The results of these studies will likely inform the HAS’s updated recommendations. A study published in ScienceDirect noted that by age 85, the average white woman has a BMD T-score of −2.5, the threshold for diagnosing osteoporosis. This research highlights the prevalence of osteoporosis in aging populations.
The French health authority’s decision will be closely watched by healthcare professionals and patients worldwide. Evenity is approved in several countries, including the United States, Canada, and Japan, but its use is often subject to similar restrictions and ongoing monitoring. The outcome of the re-evaluation could influence treatment guidelines and access to the drug in other regions.
What to Expect Next
The HAS is currently soliciting feedback from stakeholders as part of the re-evaluation process. A final decision is expected in the coming months. The agency will publish its updated recommendations, which will outline the conditions under which Evenity can be reimbursed and used in clinical practice.
Patients with osteoporosis should discuss their treatment options with their healthcare providers. It is vital to consider individual risk factors, medical history, and preferences when making decisions about osteoporosis management. The HAS’s re-evaluation of Evenity underscores the importance of ongoing research and careful monitoring of new therapies to ensure that they are both safe and effective.
The re-evaluation of Evenity highlights the dynamic nature of medical decision-making and the commitment of health authorities to ensuring that patients have access to the most appropriate and effective treatments. As new evidence emerges, guidelines will continue to evolve, reflecting the latest scientific understanding of osteoporosis and its management.
Stay tuned to World Today Journal for further updates on this developing story. We will continue to provide accurate and timely information on medical innovations and healthcare policy changes that impact global health.
Do you have questions about osteoporosis or Evenity? Share your thoughts in the comments below.